1. Home
  2. MRKR vs SONM Comparison

MRKR vs SONM Comparison

Compare MRKR & SONM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRKR
  • SONM
  • Stock Information
  • Founded
  • MRKR N/A
  • SONM 1999
  • Country
  • MRKR United States
  • SONM United States
  • Employees
  • MRKR N/A
  • SONM N/A
  • Industry
  • MRKR Biotechnology: Pharmaceutical Preparations
  • SONM Telecommunications Equipment
  • Sector
  • MRKR Health Care
  • SONM Telecommunications
  • Exchange
  • MRKR Nasdaq
  • SONM Nasdaq
  • Market Cap
  • MRKR 13.7M
  • SONM 12.6M
  • IPO Year
  • MRKR N/A
  • SONM 2019
  • Fundamental
  • Price
  • MRKR $0.89
  • SONM $0.59
  • Analyst Decision
  • MRKR Strong Buy
  • SONM
  • Analyst Count
  • MRKR 3
  • SONM 0
  • Target Price
  • MRKR $13.17
  • SONM N/A
  • AVG Volume (30 Days)
  • MRKR 2.6M
  • SONM 264.5K
  • Earning Date
  • MRKR 08-14-2025
  • SONM 08-08-2025
  • Dividend Yield
  • MRKR N/A
  • SONM N/A
  • EPS Growth
  • MRKR N/A
  • SONM N/A
  • EPS
  • MRKR N/A
  • SONM N/A
  • Revenue
  • MRKR $5,388,071.00
  • SONM $57,917,000.00
  • Revenue This Year
  • MRKR N/A
  • SONM $127.68
  • Revenue Next Year
  • MRKR $15.82
  • SONM N/A
  • P/E Ratio
  • MRKR N/A
  • SONM N/A
  • Revenue Growth
  • MRKR 44.55
  • SONM N/A
  • 52 Week Low
  • MRKR $0.81
  • SONM $0.52
  • 52 Week High
  • MRKR $5.95
  • SONM $6.38
  • Technical
  • Relative Strength Index (RSI)
  • MRKR 30.85
  • SONM 45.98
  • Support Level
  • MRKR $0.81
  • SONM $0.57
  • Resistance Level
  • MRKR $0.98
  • SONM $0.61
  • Average True Range (ATR)
  • MRKR 0.10
  • SONM 0.04
  • MACD
  • MRKR -0.03
  • SONM 0.02
  • Stochastic Oscillator
  • MRKR 14.39
  • SONM 77.31

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.

About SONM Sonim Technologies Inc.

Sonim Technologies Inc is a provider of ultra-rugged mobile devices, including phones and accessories designed specifically for task workers physically engaged in their work environments, often in mission-critical roles. The company sells mobile phones, accessories, and solutions to AT&T, T-Mobile, and Verizon in the Canada, and to Bell, Rogers, and Telus and Rogers, Telstra in Australia. The products include rugged mobile phones that can attach to both public and private wireless networks, industrial-grade accessories that meet the requirements of specific applications and software applications, and cloud-based tools that provide management and deployment services to customers. The company generates revenue from discounts, price protection, and customer incentives.

Share on Social Networks: